Efficacy and toxicity hypofractionated radiotherapy for centrally located non-small cell lung cancer. (17th May 2023)

• Record Type: Journal Article
• Authors: Janjua, Tanzeel; Sun, Fei; Clarke, Katy; Dickinson, Pete; Franks, Kevin; Arunsingh, Moses; Teo, Mark; Jain, Pooja
• Is Part Of: Journal of radiotherapy in practice. Volume 22(2023)
• Publication Date: 2023-05-17
• Subjects: central NSCLC -- hypofractionated radiotherapy -- radiotherapy toxicity; Radiotherapy -- Periodicals; 615.842005
• DOI: 10.1017/S1460396921000376
• Languages: English
• ISSNs: 1460-3969

Abstract

Abstract: Aim: Centrally located early-stage non-small cell lung cancer in patients who are unfit for surgery are treated with fractionated radiotherapy. We present the outcomes of a moderately hypofractionated accelerated dose regimen of 50 Gy in 15 fractions from a single centre in the UK. Materials and methods: Electronic case notes and radiotherapy records of lung cancer patients treated between January 2014 and December 2016 were retrospectively reviewed. Adult Comorbidity Evaluation-27 score was used to evaluate comorbidities. Mean lung doses and percentage of lung receiving more than 20 Gy were calculated for all patients. Survival outcomes were estimated using Kaplan–Meier curves. Results: Fifty-three patients were included in the study; the median follow-up was 20.2 months. 87% of patients had stage I disease. There was no 30-day post-treatment mortality. Ninety-day mortality rate after radiotherapy was 3.8%. Grade 2 pneumonitis was seen in five patients while no grade 3 or 4 pneumonitis was observed. The median progression-free survival (PFS) and overall survival (OS) were 18.5 months and 28.2 months, respectively. The estimated 1 and 2 years PFS were 62.3% and 41.3%, respectively, and OS were 77.4% and 56.6%, respectively. Worsening performance status was associated with worse survival on cox regression analysis. Disease relapsed in 36% of patients. 7.5% of patients with relapsed disease had infield recurrence. Findings: 50 Gy in 15 fractions radiotherapy for central early-stage lung cancer is a feasible choice that requires further randomised trials.